Inhalation Sciences to present findings of PreciseInhale clinical study at DDL 2022
(Stockholm 20 September 2022) ISAB’s conference paper on its study validating PreciseInhale® for clinical use has been accepted by the Drug Delivery to the Lungs (DDL) conference 2022 - one of the inhalation markets’ most influential events. The study demonstrates that PreciseInhale® outperformed standard commercial inhalers and improved ‘regional targeting’ of aerosols to specific areas of the lungs. The data will be presented as a Poster at the event.
DDL 2022 (7- 9 December, Edinburgh, Scotland) will be a particularly important event as it will be the first to be held entirely onsite again following the Covid-19 pandemic. Attendance is expected to be high.
Inhalation Sciences AB (ISAB) will present data for the first time from its study validating PreciseInhale® for clinical use. The data demonstrate that controlled, precision dosing of human subjects via PreciseInhale® outperformed aerosol dosing carried out with a standard commercial inhaler – decreasing throat deposition, decreasing standard deviation in its PK data and improving targeting of aerosols to specified major regions of the respiratory tract.
ISAB’s CEO Manoush Masarrat: “We have long been loyal attendees of DDL. This year we look forward to sharing these important findings from our clinical study with partners and prospects from across the industry.”
About the clinical study
Twelve healthy volunteers took part in the clinical Study into PreciseInhale®, ISAB’s precision dosing aerosol system. Clinical validation, which has been a long-term strategic goal for ISAB, makes PreciseInhale® the first aerosol generating system that can be used from drug discovery, through preclinical studies into first use in humans, reducing risk and translational errors throughout the drug development journey. This will, once again, show the enormous potential of ISAB’s technology beyond the preclinical market with an estimated market value of 5 billion SEK.
